IMAJ | volume 26
Journal 1, January 2024
pages: 49-51
1 Department of Medicine C, Wolfson Medical Center, Holon, Israel
2 Department of Rheumatology, Wolfson Medical Center, Holon, Israel
3 Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Summary
Paraneoplastic syndromes are reported in 8–15% of patients diagnosed with cancer [1]. They are defined as syndromes that occur due to an underlying malignancy, which has yet to be diagnosed, or at the time of the diagnosis and less frequently following the diagnosis of a malignancy. Several mechanisms are involved including autocrine and paracrine mediators, hormones, peptides, cytotoxic lymphocytes, and cytokines [1,2].